## **Core Concept**
Denosumab is a monoclonal antibody used in the treatment of conditions associated with bone resorption. It targets the **RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand) receptor**, which plays a crucial role in the regulation of osteoclast activity and bone resorption.

## **Why the Correct Answer is Right**
Denosumab works by binding to RANKL, preventing its interaction with the RANK receptor on osteoclasts and thereby inhibiting osteoclast formation, function, and survival. This mechanism leads to a decrease in bone resorption. The correct answer, **. Osteoporosis, treatment of bone loss in cancer patients, and giant cell tumor of bone**, reflects the therapeutic applications of denosumab. It is used to treat osteoporosis in postmenopausal women and men, to reduce the risk of vertebral fractures, and to treat bone loss in patients with prostate cancer, breast cancer, and other cancers.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because while denosumab does have applications in oncology, stating it only treats bone loss in cancer patients overlooks its use in osteoporosis and giant cell tumor of bone.
- **Option B:** This option is incorrect as it does not accurately represent the full scope of denosumab's therapeutic uses. Denosumab's role extends beyond just osteoporosis and cancer-related bone loss.
- **Option C:** This option might seem plausible but is incomplete. Denosumab's use in giant cell tumor of bone and other conditions like treatment of bone loss in cancer patients makes this option less accurate.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that denosumab is administered via subcutaneous injection. A notable side effect is the increased risk of **osteonecrosis of the jaw (ONJ)**, and it is recommended that patients have a dental evaluation before starting treatment and periodically thereafter.

## **Correct Answer:** . Osteoporosis, treatment of bone loss in cancer patients, and giant cell tumor of bone